Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

GenScript Biotech Collaborates with T-MAXIMUM Biotech

Thursday, August 10, 2023

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration agreement to advance the development of T-MAXIMUM's CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents.

This collaboration between GenScript Biotech and T-MAXIMUM Biotech represents a concerted effort to leverage each other's strengths and expertise in order to expedite the development of innovative CAR-T cell therapy solutions for patients, especially those with solid tumours.

This partnership entails GenScript providing various CRISPR reagents to T-MAXIMUM Biotech, which will assist in the entire process of developing universal CAR-T products, from the initial discovery phase to eventual commercialisation.

This collaboration is expected to streamline the regulatory procedures both in China and the United States, facilitating quicker progress of T-MAXIMUM's product pipeline and subsequently benefiting patients in need at an earlier timeframe.

The focus of the collaboration is on utilising R&D-to-GMP-level sgRNA to bolster the development of UCAR-T products targeting solid tumours. While CAR-T therapies have shown promising results in treating haematological tumours, addressing the significant challenges associated with solid tumours is crucial for further advancements in the field of cell-based therapies.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024